Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
| Autor: | Kyriakopoulos, Christos, Chatta, Gurkamal S., Laccetti, Andrew Leonard, Iannotti, Nicholas, Sokolova, Alexandra, Hotte, Sebastien J., Tutrone, Ronald F., Markowski, Mark Christopher, Nordquist, Luke T., Pili, Roberto, Saad, Fred, Zhang, Jingsong, Villaluna, Karen, Younginger, Brett, Le Moigne, Ronan, Cesano, Alessandra |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p141-141, 235p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|